NCT03608293

Brief Summary

Cigarette smoking is a habit that has spread all over the world and is a significant risk factor for many diseases including cardiovascular disease, chronic obstructive pulmonary disease(COPD),asthma and lung cancer. Evaluation and understanding of tobacco health effects are of major interest worldwide and answer to important societal concerns. Identification of new biomarkers of exposure to tobacco smoke potentially implicated in COPD or lung carcinogenesis would allow a better observation of tobacco exposed population, thanks to screening establishment at reversible stages of pathological processes. In this study, we question whether cigarettes smoking alters miRNA profiles of extracellular vesicles (EVs) present in human broncho alveolar lavages (BALs), which could affect surrounding normal bronchial epithelial cells status.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2012

Typical duration for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2013

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2013

Completed
4.6 years until next milestone

First Submitted

Initial submission to the registry

July 24, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 31, 2018

Completed
Last Updated

July 31, 2018

Status Verified

July 1, 2018

Enrollment Period

1.6 years

First QC Date

July 24, 2018

Last Update Submit

July 24, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Quantification of target mRNA expression in human bronchial epithelial cells (BEAS-2 B) exposed to EVs isolated from LBA of patients

    Quantitative polymerase chain reaction (RT-qPCR) for determination of mRNA expression

    Through the study completion, an average of 48 months

Study Arms (2)

Smokers

EXPERIMENTAL

Smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed

Diagnostic Test: Broncho Alveolar Lavages (BAL)

Non smokers

ACTIVE COMPARATOR

Non smokers outpatients at the Pneumology service from the HôpitalSaint-Philibert (Lomme, France) to whom a bronchoalveolar lavage will be performed

Diagnostic Test: Broncho Alveolar Lavages (BAL)

Interventions

BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.

Non smokersSmokers

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \>18 year-old

You may not qualify if:

  • Lack of informed consent
  • Drug treatment
  • Professional exposure
  • Evolutive pregnancy
  • Bradycardia
  • Respiratory assistance required,
  • Diagnosed respiratory distress (e.g. COPD, asthma)
  • Infectious pneumopathy
  • Bronchial cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Pierre Gosset, MD

    GHICL

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 24, 2018

First Posted

July 31, 2018

Study Start

January 1, 2012

Primary Completion

July 31, 2013

Study Completion

December 31, 2013

Last Updated

July 31, 2018

Record last verified: 2018-07